Author
NHD Technical Team
NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.
-
Evidence & Quality Guides
GHK-Cu Topical vs Injectable Evidence: A Route-Specific Quality Boundary
-
Published Study Reviews
LL-37 at the Ocular Surface: Expression and In-Vitro Antimicrobial Data
-
Evidence & Quality Guides
LL-37 Evidence Boundaries: Endogenous Peptide, Engineered Delivery and Catalog Material
-
Published Study Reviews
MOTS-c in the 2015 Cell Metabolism Paper: Cells, Mice and the Human Evidence Gap
-
Evidence & Quality Guides
MOTS-c “Human”: What the Label Means, and What FDA Says Is Still Missing
-
Published Study Reviews
Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context
-
Evidence & Quality Guides
Survodutide Research Status: Dual Glucagon/GLP-1 Biology, Trials and Material Identity
-
Published Study Reviews
Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show
-
Quality & Documentation
How to Read a Peptide COA: Batch Identity, Tests, Limits and Results
-
Quality & Documentation
HPLC Area Purity vs Assay: Why a 99% Peak Is Not 99% Peptide Content
-
Quality & Documentation
Reading LC-MS Peptide Identity: Exact Mass, Isotope Envelopes and MS/MS
-
Quality & Documentation
Peptide Counterions, Water and Residual Solvents: Interpreting Net Content